A Houston-based company is beginning a push on its proven test for central nervous system (CNS) cancers.

“We're going to start rolling out just in Texas and doing patient testing in the state of Texas, first with a few accounts where we've established a relationship, and then we'll continue our rollout through the United States in the next year or so,” says Russell Bradley, president and general manager of CNSide Diagnostics.

Bradley had retired from multinational diagnostics company Abbott Laboratories when he met Marc Hendrick, the CEO of Austin’s Plus Therapeutics, last year. When Hendrick told him about the recent acquisition of CNSide, a company formerly based in San Diego, Bradley says he felt compelled to join in its mission.

CNSide’s CSF assay tests cerebrospinal fluid for cancers that have metastasized to the spine or brain, primarily carcinomas and melanomas.

“Typically, they do an MRI, and that won't always show anything. If it's early stage, they do cytology, which is not very sensitive at finding cancer cells in the cerebrospinal fluid. By the time they're diagnosed, it can be very late-stage, and oftentimes, in fact, the studies show that half of these patients don't get treated,” Bradley says.

CNSide, then, is a ray of hope for patients who are often consigned to palliative care. By diagnosing their metastasis sooner, physicians have more treatment options to stop the CNS cancer before it’s wreaked havoc. Bradley also points out that once a treatment regimen is underway, doctors can continue to measure the cancer’s progress or lack thereof. He claims that, of the roughly 300 neuro-oncologists in the United States, about 200 have already used the test.

Moving from California to Houston briefly slowed progress for CNSide, but now, matters are moving ahead at a steady clip.

“It takes a little bit of time to establish the test in a new location, move the apparatus and establish the processes,” Bradley says. “You have to get the lab accredited, which we just did. So we're now accredited to run patient samples, and we've really just been doing our research samples as part of the clinical studies.”

Texas institutions, such as the University of Texas - Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health and Texas Oncology, are beginning to use the technology.

Bradley, who lives in Austin but spends much of his time in Houston, says that the city has been nothing less than an ideal fit for the needs of his growing company and a lab that’s currently hiring. He praises the logistics potential of being close to a major hub, which will eventually be a key factor for getting lumbar puncture samples from around the country to the lab for quick testing.

“I think the business environment in Texas, generally, and in Houston, specifically, for us and the access to talent with a lot of institutions here around the Houston area that graduate the type of people that we want to employ is remarkable. And I'd say the cherry on top is really just access to world-class institutions like MD Anderson. I think from a holistic and comprehensive point of view, Houston has a lot to offer a company like us,” Bradley says.

And ultimately, what brought Bradley and CNSide to Texas is the quest to prolong the lives of people living with cancer. As he puts it, “It's a true privilege—and I know I speak on behalf of the team at CNSide and Plus—to be able to impact these patients and have the tools at this time in the history of cancer diagnostics to be able to really make a difference.”